Compare CRMT & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRMT | LSTA |
|---|---|---|
| Founded | 1981 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 15.9M |
| IPO Year | 2026 | 2000 |
| Metric | CRMT | LSTA |
|---|---|---|
| Price | $0.94 | $1.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | ★ $7.50 | N/A |
| AVG Volume (30 Days) | ★ 401.0K | 81.1K |
| Earning Date | 12-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,281,502,000.00 | $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.29 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.57 | $0.96 |
| 52 Week High | $28.70 | $5.07 |
| Indicator | CRMT | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 40.84 | 35.24 |
| Support Level | $0.95 | $0.99 |
| Resistance Level | $1.49 | $1.28 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 45.56 | 11.58 |
America's Car-Mart Inc is an automotive retailer in the U.S. focused exclusively on the Integrated Auto Sales and Finance segment of the used car market. The company's operations are principally conducted through its two operating subsidiaries, America's Car Mart Inc and Colonial Auto Finance. It predominantly sells older model used vehicles and provides financing for substantially all of its customers. It earns revenue from the sale of used vehicles and, in the majority of cases, a related service contract and an accident protection plan product, as well as interest income and late fees from the related financing.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.